Journal article · 2026 · Open access

Development of Potent METTL1 Inhibitors Using a Nanoscale Direct-To-Biology Strategy

Valerie Kadenbach, Zarina Nidoieva, Mark O. Sabin, David Schmidl, Franziska Krähe, Annabelle Carolin Weldert, Tristan M. Dewald, Ariane F. Hübner, Michaela Frye, Fabian Barthels

Journal of Medicinal Chemistry · Published 5 November 2026 · DOI 10.1021/acs.jmedchem.6c01297

Open PDFView at the publisherCite this paper

In brief

“Development of Potent METTL1 Inhibitors Using a Nanoscale Direct-To-Biology Strategy” is a 2026 journal article by Valerie Kadenbach and 9 co-authors, published in Journal of Medicinal Chemistry. OpenAlex counts 0 citations as of 17 November 2026. It is open access under a CC BY licence: the full text is free to read at Journal of Medicinal Chemistry.

Citations
0
References
79
Authors
10

Abstract

The RNA methyltransferase METTL1/WDR4, which catalyzes N7-methylguanosine (m7G) modification in tRNA, has emerged as a key regulator of mRNA translation, and its dysregulation is associated with cancer development. Here, we report the development of a potent series of METTL1 inhibitors by combining conventional structure−activity relationship (SAR) studies with a tandem direct-to-biology (D2B) approach. Lead compound VK238 inhibited METTL1 enzymatic activity at nanomolar concentrations and exhibited selectivity across a panel of methyltransferases and kinases. In a cellular context, pharmacological METTL1 inhibition reduced m7G levels in tRNAs, leading to apoptosis-mediated cell death in several acute myeloid leukemia (AML) cell lines. Mechanistic studies combining biophysical experiments, photoaffinity labeling (PAL), and molecular docking suggested that this inhibitor series occupies the (S)-adenosylmethionine (SAM) binding pocket of METTL1. Collectively, these findings highlight METTL1 as a tractable and pharmacologically relevant target for therapeutic intervention in AML.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Kadenbach, V., Nidoieva, Z., Sabin, M. O., Schmidl, D., Krähe, F., Weldert, A. C., Dewald, T. M., Hübner, A. F., Frye, M., & Barthels, F. (2026). Development of Potent METTL1 Inhibitors Using a Nanoscale Direct-To-Biology Strategy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01297

MLA 9

Kadenbach, Valerie, et al. “Development of Potent METTL1 Inhibitors Using a Nanoscale Direct-To-Biology Strategy.” Journal of Medicinal Chemistry, 2026. https://doi.org/10.1021/acs.jmedchem.6c01297.

Chicago

Kadenbach, Valerie, Zarina Nidoieva, Mark O. Sabin, David Schmidl, Franziska Krähe, Annabelle Carolin Weldert, Tristan M. Dewald, Ariane F. Hübner, Michaela Frye, and Fabian Barthels. 2026. “Development of Potent METTL1 Inhibitors Using a Nanoscale Direct-To-Biology Strategy.” Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01297.

Harvard

Kadenbach, V. et al. (2026) ‘Development of Potent METTL1 Inhibitors Using a Nanoscale Direct-To-Biology Strategy’, Journal of Medicinal Chemistry. doi:10.1021/acs.jmedchem.6c01297.

IEEE

V. Kadenbach et al., “Development of Potent METTL1 Inhibitors Using a Nanoscale Direct-To-Biology Strategy,” Journal of Medicinal Chemistry, 2026, doi: 10.1021/acs.jmedchem.6c01297.

BibTeX

@article{kadenbach2026development,
  title     = {{Development of Potent METTL1 Inhibitors Using a Nanoscale Direct-To-Biology Strategy}},
  author    = {Kadenbach, Valerie and Nidoieva, Zarina and Sabin, Mark O. and Schmidl, David and Krähe, Franziska and Weldert, Annabelle Carolin and Dewald, Tristan M. and Hübner, Ariane F. and Frye, Michaela and Barthels, Fabian},
  journal   = {Journal of Medicinal Chemistry},
  year      = {2026},
  doi       = {10.1021/acs.jmedchem.6c01297},
  url       = {https://doi.org/10.1021/acs.jmedchem.6c01297}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer

  • METTL1
  • WDR4
  • 7-methylguanosine
  • tRNA methylation
  • structure-activity relationship
  • acute myeloid leukemia
  • apoptosis
  • photoaffinity labeling

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Kadenbach, V., Nidoieva, Z., Sabin, M. O., Schmidl, D., Krähe, F., Weldert, A. C., Dewald, T. M., Hübner, A. F., Frye, M., & Barthels, F. (2026). Development of Potent METTL1 Inhibitors Using a Nanoscale Direct-To-Biology Strategy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01297

How many times has this paper been cited?

0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Journal of Medicinal Chemistry: sign in and open the PDF from this page.

Who wrote this paper?

Valerie Kadenbach, Zarina Nidoieva, Mark O. Sabin, David Schmidl, Franziska Krähe, Annabelle Carolin Weldert, Tristan M. Dewald, Ariane F. Hübner, Michaela Frye, Fabian Barthels.

What is the DOI of this paper?

10.1021/acs.jmedchem.6c01297, permanently at https://doi.org/10.1021/acs.jmedchem.6c01297. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.